iRNA agents targeting VEGF
First Claim
Patent Images
1. An isolated double stranded iRNA agent, consisting of SEQ ID NO:
- 609 and SEQ ID NO;
608.
3 Assignments
0 Petitions
Accused Products
Abstract
The features of the present invention relate to compounds, compositions and methods useful for modulating the expression of vascular endothelial growth factor (VEGF), such as by the mechanism of RNA interference (RNAi). The compounds and compositions include iRNA agents that can be unmodified or chemically-modified.
42 Citations
10 Claims
-
1. An isolated double stranded iRNA agent, consisting of SEQ ID NO:
- 609 and SEQ ID NO;
608. - View Dependent Claims (8, 9, 10)
- 609 and SEQ ID NO;
-
2. An isolated double stranded iRNA agent consisting of SEQ ID NO:
- 608 and SEQ ID NO;
609 and a non-nucleotide moiety. - View Dependent Claims (3)
- 608 and SEQ ID NO;
-
4. An isolated double stranded iRNA agent consisting of SEQ ID NO:
- 608 and SEQ ID NO;
609 and a phosphorothioate at the first internucleotide linkage at the 5′
end of the antisense and sense sequences.
- 608 and SEQ ID NO;
-
5. An isolated double stranded iRNA agent consisting of SEQ ID NO:
- 608 and SEQ ID NO;
609 and a phosphorothioate at the first internucleotide linkage at the 5′
end of the antisense and sense sequences, and a phosphorothioate at the first internucleotide linkage at the 3′
end of the antisense and sense sequences.
- 608 and SEQ ID NO;
-
6. An isolated double stranded iRNA agent consisting of SEQ ID NO:
- 608 and SEQ ID NO;
609 and wherein at least one nucleotide of at least one strand is a 2′
-modified nucleotide. - View Dependent Claims (7)
- 608 and SEQ ID NO;
Specification